Appropriate use of factor VIII in the treatment of hemophilia A - consensus conference
Andalusian Agency for Health Technology Assessment
Record ID 32001000091
Spanish
Authors' objectives:
The results of this consensus conference are reported with the aim of supporting and facilitating the decision-making process for managers and clinicians related to haemophiliac patients' care.
Authors' recommendations:
Overall, the panel considered previously untreated patients without HIV infection appropriate indications for recombinant factor VIII (FCIII), both for therapy and prophylaxis. In the same way, high purity plasmatic products were considered appropriate for HIV seropositive patients, regardless of previous treatment or severity. The panel were divided and considered uncertain the indication any product for moderate or severe previously treated patients, without HIV infection.
Finally, the expert groupmade some general recommendations in regard to haemophilia therapy, as the need to assure double viral inactivation procedures for plasmatic products, and a demonstrated altruistic source. Also, the group remarked on the importance of following the principles of appropriate and rational use of treatments, including the active surveillance of any adverse effects, and rigorous assessment of future developments. Patients' participation in decision-making processes must be considered as an essential element in treatment and care, and therefore it was proposed to discuss current scientific knowledge and the proposals of this report with patients' organisations.
Details
Project Status:
Completed
URL for project:
https://www.aetsa.org/publicacion/uso-adecuado-de-factor-viii-en-el-tratamiento-de-la-hemofilia-a/
Year Published:
2000
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_P_2000_Factor8.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Factor VIII
- Hemophilia A
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.